Efficacy of single dose intravenous dexamethasone compared with three-day oral dexamethasone for prevention of pemetrexed-induced skin adverse reactions

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230111003

Enrollment

Registered

2023-01-11

Start date

2022-12-27

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pemetrexed-induced cutaneous adverse reactions pemetrexed rash dexamethasone

Interventions

dexamethasone (4) 1 tab po bid for 3 days,dexamethasone 10 mg iv

Active Comparator Drug,Experimental Drug

oral three-day dexamethasone,single dose intravenous dexamethasone

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. age more than 17 2. no prior exposure to pemetrexed 3. planned to receive single agent pemetrexed 4. ECOG 0-2 5. signed inform consent

Exclusion criteria

Exclusion criteria: 1. history of severe drugs and food allgery 2. active skin diseases 3. systemic steriod use 7 days prior to enrollment 4. on other immunosuppressive drugs 5. chronic kidney disease stage IV 6. uncontrolled diabetes

Design outcomes

Primary

Measure	Time frame
Grade 3 and 4 cutaneous adverse reactions 7-21 days after pemetrexed treatment CTCAE	—

Secondary

Measure	Time frame
All grade cutaneous adverse reactions 7-21 days after pemetrexed treatment CTCAE	—

Countries

Thailand

Contacts

Public ContactKanta Riensavapak

Faculty of Medicine, Chulalongkorn University

kanta.riens@gmail.com0909713342

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026